全文获取类型
收费全文 | 1686453篇 |
免费 | 113723篇 |
国内免费 | 2419篇 |
专业分类
耳鼻咽喉 | 23532篇 |
儿科学 | 55761篇 |
妇产科学 | 47820篇 |
基础医学 | 256676篇 |
口腔科学 | 45476篇 |
临床医学 | 146068篇 |
内科学 | 323785篇 |
皮肤病学 | 36077篇 |
神经病学 | 126076篇 |
特种医学 | 65425篇 |
外国民族医学 | 410篇 |
外科学 | 257630篇 |
综合类 | 32892篇 |
现状与发展 | 2篇 |
一般理论 | 399篇 |
预防医学 | 123653篇 |
眼科学 | 38983篇 |
药学 | 128777篇 |
2篇 | |
中国医学 | 3360篇 |
肿瘤学 | 89791篇 |
出版年
2018年 | 16253篇 |
2016年 | 13862篇 |
2015年 | 15820篇 |
2014年 | 21645篇 |
2013年 | 32720篇 |
2012年 | 45902篇 |
2011年 | 49649篇 |
2010年 | 29124篇 |
2009年 | 27024篇 |
2008年 | 47275篇 |
2007年 | 51484篇 |
2006年 | 51775篇 |
2005年 | 50438篇 |
2004年 | 48768篇 |
2003年 | 47387篇 |
2002年 | 46396篇 |
2001年 | 74477篇 |
2000年 | 76441篇 |
1999年 | 64590篇 |
1998年 | 18252篇 |
1997年 | 16082篇 |
1996年 | 16365篇 |
1995年 | 15413篇 |
1994年 | 14488篇 |
1993年 | 13552篇 |
1992年 | 51587篇 |
1991年 | 51974篇 |
1990年 | 51551篇 |
1989年 | 50220篇 |
1988年 | 46743篇 |
1987年 | 45937篇 |
1986年 | 43578篇 |
1985年 | 41653篇 |
1984年 | 31046篇 |
1983年 | 26872篇 |
1982年 | 15562篇 |
1981年 | 13866篇 |
1979年 | 29578篇 |
1978年 | 20829篇 |
1977年 | 17777篇 |
1976年 | 17237篇 |
1975年 | 19348篇 |
1974年 | 22587篇 |
1973年 | 21770篇 |
1972年 | 20545篇 |
1971年 | 19293篇 |
1970年 | 18009篇 |
1969年 | 17143篇 |
1968年 | 16165篇 |
1967年 | 14331篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Nicola Flaum Emma J. Crosbie Richard J. Edmondson Miriam J. Smith Dafydd G. Evans 《Clinical genetics》2020,97(1):54-63
Ovarian cancer is the fourth most common cause of cancer-related death in women in the developed world, and one of the most heritable cancers. One of the most significant risk factors for epithelial ovarian cancer (EOC) is a family history of breast and/or ovarian cancer. Combined risk factors can be used in models to stratify risk of EOC, and aid in decisions regarding risk-reduction strategies. Germline pathogenic variants in EOC susceptibility genes including those involved in homologous recombination and mismatch repair pathways are present in approximately 22% to 25% of EOC. These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) thought to explain an additional 6.4% of the familial risk of ovarian cancer, with 34 susceptibility loci identified to date. However, an unknown proportion of the genetic component of EOC risk remains unexplained. This review comprises an overview of individual genes and SNPs suspected to contribute to risk of EOC, and discusses use of a polygenic risk score to predict individual cancer risk more accurately. 相似文献
82.
Thomas W. McDade Alexander V. Georgiev Christopher W. Kuzawa 《Evolution, Medicine, and Public Health》2016,2016(1):1-16
Immune defenses provide resistance against infectious disease that is critical to survival. But immune defenses are costly, and limited resources allocated to immunity are not available for other physiological or developmental processes. We propose a framework for explaining variation in patterns of investment in two important subsystems of anti-pathogen defense: innate (non-specific) and acquired (specific) immunity. The developmental costs of acquired immunity are high, but the costs of maintenance and activation are relatively low. Innate immunity imposes lower upfront developmental costs, but higher operating costs. Innate defenses are mobilized quickly and are effective against novel pathogens. Acquired responses are less effective against novel exposures, but more effective against secondary exposures due to immunological memory. Based on their distinct profiles of costs and effectiveness, we propose that the balance of investment in innate versus acquired immunity is variable, and that this balance is optimized in response to local ecological conditions early in development. Nutritional abundance, high pathogen exposure and low signals of extrinsic mortality risk during sensitive periods of immune development should all favor relatively higher levels of investment in acquired immunity. Undernutrition, low pathogen exposure, and high mortality risk should favor innate immune defenses. The hypothesis provides a framework for organizing prior empirical research on the impact of developmental environments on innate and acquired immunity, and suggests promising directions for future research in human ecological immunology. 相似文献
83.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
84.
85.
86.
87.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
88.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.89.
90.